A pair of former GlaxoSmithKline scientists specializing in neurosciences has grabbed $18.4 million in venture backing to launch a startup biotech pursuing a pipeline of programs spun out of the pharma giant.
The FDA gave the OK to GlaxoSmithKline's new four-strain seasonal flu vaccine, which the company said will become available for the 2013-2014 flu season.
GlaxoSmithKline's commonly used antidepressant paroxetine (Paxil) could have a new life as a treatment for diabetic vascular complications, according to preclinical results coming out of the University of Texas Medical Branch at Galveston.
The FDA is wrapping up business before the end of the year and making a flurry of approvals. The agency OK'd three new drugs Friday, with all of the green-lighted therapies sanctioned for combating relatively rare ailments and securing orphan drug status.
GlaxoSmithKline ($GSK) nabbed FDA approval for its new influenza vaccine Fluarix Quadrivalent.
At the University of Dundee, researchers engineered the system to mimic the iterative approach of medicinal chemists as they craft compounds to deliver the safety and efficacy profiles needed to combat diseases.
Another marketing settlement has been wrung out of a Big Pharma player, with Pfizer ($PFE) this time paying $55 million and change to clear up a problem it acquired.
An era of Big Data hype seems to be waning as people in the biopharma game and other industries wake up and start asking tough questions about the value of unimaginable amounts of information. Executive Editor Ryan McBride will be monitoring FierceBiotech 's " Big Data in Biopharma Forum " on Jan. 9 in San Francisco. Register here.
The global pediatric vaccine market will likely hit a value of more than $23 billion by 2015, a market analysis shows. GlaxoSmithKline leads the charge with nearly a quarter of the global market.
The GAVI Alliance wants to immunize 30 million girls worldwide with HPV vaccines by 2020.